Abstract
BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) revolutionized cancer treatment and cancer immunotherapy. However, the majority of patients with metastatic disease do not achieve durable response following treatment...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
